Review
Sep 2026
Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers
The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.
Srijita Chatterjee, S. Arya, Nidhi Sharma et al.
· Medical Oncology · 0 citations